SEQUENCE trial data highlight sustained 3-year clinical and endoscopic remission with risankizumab in anti-TNF–exposed Crohn’s patients.
Raja Atreya, MD
Advertisement
Raja Atreya, MD, is head of the IBD Center at University Hospital of Erlangen.
Articles by Raja Atreya, MD
Advertisement